In conclusion, we propose that modulation of the dynorphin/KOR system is a promising target for addressing hyperalgesia and hyperkatifeia during opioid withdrawal, which could potentially be used for the treatment of opioid use disorder and addiction more generally. This evidence concerns the gene OPRK1 and opioid use disorder.